Trial | NCT00292487  Report issue

Title

Patients With Renal Impairment Undergoing CT
Isovue and Visipaque in Renally Impaired Patients Undergoing CT

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    iopamidol ...

  • Study Participants

    150
The purpose of the study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue or Visipaque in patients with mild to moderate renal impairment who undergo a clinically indicated IV contrast-enhanced (multidetector computed tomography) MDCT of the liver or MDCT angiography of the lower extremities. Serum Creatinine (SCr) will be measured before and up to 48-72 hours post dose.
Study Started
Nov 30
2004
Primary Completion
Feb 28
2006
Study Completion
Feb 28
2006
Last Update
Feb 08
2012
Estimate

Drug Iopamidol 370 mgI/mL

Criteria 

Inclusion Criteria:

referred for MDCT of liver or peripheral CTA
stable baseline SCr of 1.5 - 2.5 mg/dL and/or calculated CrCl of 10-60 mL/min

Exclusion Criteria:

unstable renal function
required prophylactic drugs to receive contrast (other than hydration)
uncontrolled diabetes
currently on dialysis
No Results Posted